2024-10-01 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

###  1. Performance Comparison

Johnson & Johnson (JNJ) has significantly underperformed the S&P 500 (VOO) over the analyzed period. While VOO has generated a cumulative return of 133.28%, JNJ has returned only 36.05%, resulting in a **cumulative return difference of -97.23%.**  This places JNJ's performance at the **7.11% percentile** relative to its historical performance range.

### 2. Recent Price Movement

JNJ's stock price has been relatively stable recently. 

* **Closing price:** $162.82
* **5-day moving average:** $162.08
* **20-day moving average:** $164.91
* **60-day moving average:** $159.96

The stock is currently trading slightly below its 20-day moving average, suggesting potential for upward movement, but remains below its 60-day moving average, which indicates long-term price weakness. 

### 3. Technical Indicators

* **RSI:** 36.9. This suggests JNJ is currently in a **neutral** zone, not overly bought or sold.
* **PPO:** -0.47. This indicates a **potential bearish trend**, as it is below the zero line.
* **Delta_Previous_Relative_Divergence:** -5.2. The negative value indicates a **short-term downward trend** in the stock's relative performance.
* **Expected Return:** 0.0%. This signifies a **zero expected return** over the next 5 years based on current investment levels.

### 4. Recent Earnings and Outlook

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2024-07-25 | 1.95 | $22.45B      |
| 2024-05-01 | 1.35 | $21.38B      |
| 2024-02-16 | 1.68 | $21.39B      |
| 2023-10-27 | 10.32| $21.35B      |
| 2024-02-16 | 10.32| $21.35B      |

The most recent earnings report, dated 2024-07-25, revealed EPS of $1.95, surpassing analysts' expectations of $1.85. Revenue of $22.45B also exceeded forecasts. This demonstrates a **stronger than expected performance** in the latest quarter. However, the stock's price reaction following the earnings announcement was muted, potentially indicating concerns about future growth prospects.

### 5. News and Recent Developments

**Market Outlook:** The recent market outlook for JNJ is cautious. While analysts acknowledge the company's strong earnings performance, concerns regarding long-term growth in the pharmaceutical sector are prevalent. The divestiture of the consumer health business has also introduced uncertainty about the company's future direction.

**Analyst Opinions:** The consensus among analysts is that JNJ is a "hold" or "buy," with a slight edge towards "hold." The stock is considered undervalued by some analysts, with potential for growth in the long term.

**Performance Highlights:** Recent highlights include the strong earnings performance, the divestiture of the consumer health business, and ongoing legal battles related to its talcum powder products. 

**Finbold:** Finbold's recent report states that JNJ's stock price is expected to rise in the coming months, citing strong earnings and a potential for growth in the pharmaceutical industry. However, the report also warns about the company's exposure to legal risks.

### 6. Comprehensive Analysis

Johnson & Johnson's recent earnings performance was strong, exceeding analysts' expectations. However, its long-term performance has lagged behind the S&P 500, and concerns about the company's future growth potential remain. Technical indicators suggest a potential bearish trend, while analysts offer a cautiously optimistic outlook. Overall, JNJ presents a mixed picture with both potential upside and downside risks. Investors should carefully consider the company's long-term prospects and the impact of ongoing legal challenges before making any investment decisions.

### 7. Report Summary

Johnson & Johnson (JNJ) has underperformed the S&P 500 (VOO) significantly, with a cumulative return difference of -97.23%. Despite strong recent earnings performance, the stock's price movement indicates potential for a bearish trend. The company's long-term growth potential remains uncertain due to concerns regarding the pharmaceutical sector and the divestiture of its consumer health business. Investors should carefully consider the company's risks and opportunities before making any investment decisions.
